Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 104

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 104
---
,563 (1,670)(11)%Comprehensive income (loss)$(4,003,590)$12,925,219 $(16,928,809)(131)%

Revenues

Revenues for the three months ended June 30, 2025 and June 30, 2024 are related to our license agreement with Organon to commercialize XACIATO. From and after April 1, 2024, any revenue we recognize under such license agreement will be recognized as non-cash royalty revenue. See "—Financial Overview—Revenue," above for information. An adjustment for lower actual royalty revenue than we previously estimated for the three months ended March 31, 2025 resulted in the negative non-cash royalty revenue reported for the three months ended June 30, 2025. See “—Financial Overview—Revenue,” above.

General and administrative expenses

The decrease of approximately $0.1 million in general and administrative expenses for the three months ended June 30, 2025 as compared to the three months ended June 30, 2024 was primarily attributable to decreases in (i) personnel costs of approximately $0.2 million, (ii) stock-based compensation expense of approximately $0.1 million, and (iii) general corporate overhead of approximately $0.1 million. Such decreases were partially offset by an increase in professional services expense of approximately $0.3 million.

Research and development expenses

The following table summarizes our R&D expenses for the periods indicated, together with the changes in those items in terms of dollars and percentage:

37

Three Months EndedJune 30,Change20252024$%Direct program costs:Ovaprene (1)$1,316,372 $2,979,486 $(1,663,114)(56)%Sildenafil Cream, 3.6%49,881 706,403 (656,522)(93)%Other advanced clinical stage programs (1)975,489 398,633 576,856 145 %Phase 1 and Phase 1-ready clinical stage programs (1)628,595 204,894 423,701 207 %Preclinical stage programs (1)1,718,320 1,306,514 411,806 32 %Other development programs— 10,132 (10,132)(100)%Contra R&D expenses (2)(3,780,794)(1,991,167)(1